RHEUMATOID ARTHRITIS MEDICATION INCREASES RISK OF BLOOD CLOTS IN LUNGS AND INCREASES RISK OF DEATH
By David C. Harman, Burg Simpson Shareholder
The FDA has alerted the public about the increased risk of blood clots in the lungs and an increased risk of death among rheumatoid arthritis (RA) patients taking Xeljanz (tofacitinib). A safety committee found these increased risks were associated with RA patients receiving higher dosages of Xeljanz. Specifically, clinical trial data “found an increased occurrence of blood clots in the lungs and death in [RA] patients treated with tofacitinib 10 mg twice daily compared to patients with tofacitinib 5 mg twice daily.”
If you or a loved one have suffered a blood clot in the lungs or death while taking Xeljanz, contact one of the experienced defective drug attorneys at Burg Simpson today to discuss your legal rights. Call us at 1-800-713-9340 or fill out our contact form for a FREE no-obligation consultation today.